New therapeutics for pain relief has been desired.which substitutes for opioids and non-steroidal antiinflammatory drugs to evade their side effects.Recent clinical studies conducted by Pfizer and other pharmaceutical companies have shown remarkable suppression of pain in osteoarthritis patients with therapeutic antibodies against nerve growth factor (NGF).In the Pfizers phase ni clinical study,however,worsening of joints was reported and most clinical studies are now on clinical hold by US FDA since June 2010.